Patient Acess in Advanced Therapies - ATE26

Manufacturing in Advanced Therapies - ATE26

Capital flow and investment - ATE26

China's Growth in Advanced Therapies - ATE26

Regulatory Harmony in Advanced Therapies - ATE26

The #ATE26 team's conference essentials!

Meet the team behind #ATE26 and what they're most looking forward to

Advanced Therapies Europe 2026 - Sponsor Onboarding

Europe's ATMP Roadmap: Can Europe Compete? | EU Biotech Act & Horizon Europe

Advanced Therapies Europe 2026 | Barcelona | Official Trailer

Is Advanced Therapies Europe Worth Attending? Hear From 2025 Attendees

Mentorship, power and the reality of inclusive leadership | #ATW26

Regulatory engagement strategies for early stage developers | #ATW26

She Leads Biotech Podcast Live | #ATW26

Geopolitics, policy, and the new global landscape for Advanced Therapies | #ATW26

Siren Biotechnology and the power of the crowd | #ATW26

Buildings or biotech Which comes first? | #ATW26

Bio2Bedside Podcast live - Leading Responsibly in Right-To-Try Legislation | #ATW26

The role of patient advocacy in shaping early clinical development | #ATW26

Closing Keynote: Turning broken systems into breakthroughs | #ATW26

Patient-centric by design: creating therapies with the patient in mind | #ATW26

Innovation Exchange | #ATW26

Developing unbiased assays to detect replication competent AAV in clinical vector products | #ATW26

Clinical Biomarkers of Durable Response to CiltacabtageneAutoleucelin Patients | #ATW26

Lessons from building a next generation translational center | #ATW26

Opening Plenary - 2025: What Worked. What Didn’t. What Comes Next | #ATW26

Tech Transfer and Manufacturing | #ATW26

How can AI accelerate R&D for CGT? | #ATW26

Forging effective partnerships across the advanced therapy ecosystem | #ATW26

Advancing targeted in vivo LNPs | #ATW26

The commercial blind spot - Bridging the business gap for scientific founders | #ATW26

Rethinking capital – Alternative funding models for biotech | #ATW26

Patient Spotlight | #ATW26

Investment Summit Opening Keynote | #ATW26

Inside the investor’s mind: What fundable companies look like in 2026 | #ATW26

Redefining representation — Inclusive leadership for the future of advanced therapies | #ATW26

WIAT Welcoming Address & Leadership and Life Lessons from the PCT | #ATW26

Clinical data generation in CGT strategy, operations and geography | #ATW26

Beyond the pipeline: Investing in the tools and tech powering CGT | #ATW26

Building a Collaborative Cell & Gene Therapy ecosystem in Saudi Arabia

Driving consistency, Yield, and Potency in Advanced Therapies with Predictive Analytics

Vitrafy: Cryopreservation as a Controlled, Intelligent Process

Innovation from Nucleus Biologics Enables Co-located Media & Buffer Manufacturing & Bioproduction

Clinical Trail Enablement - Demistifying Clinical Trials in Europe

Unlocking Scale: Rethinking Tools for the Next Era of Cell and Gene Therapy

The role of manufacturing in improving cell immunotherapies

The Evolution of Bioprocessing Reagents

Reducing vein-to-vein time: Shorter-than-3-day sterility release for advanced therapies

Breaking the Speed–Risk Trade-off in Genomic Medicine

The Gold Standard Challenge in Advanced Therapy Biomanufacturing & Logistics

Assurea in 2026

Breaking the Bottleneck: Solving Late-Stage AAV Challenges with Real World Commercial Experience

Introducing aiMOS: AI-Driven Media Optimization for Cell Therapy

Pure Proven Precise Solutions

Limula: a platform to streamline cell therapy manufacturing, from R&D to the clinic

Beyond Raw Materials: Building Partnerships That Drive Cell Therapy Innovation

Strategic Foundation: Why Commercial Ready Manufacturing Should Be Considered from Day One

Beyond Viability: Designing Cryopreservation Systems for Cell Therapy

NKILT Therapeutics: next gen cell therapy to more cancer patients

Advanced Therapies Week 2026 Highlights | The Future of Cell & Gene Therapy